Literature DB >> 16102550

Safety of mifepristone abortions in clinical use.

Jillian T Henderson1, Ann C Hwang, Cynthia C Harper, Felicia H Stewart.   

Abstract

OBJECTIVES: Extensive data from clinical trials document mifepristone's safety and efficacy for induced abortion, but less information is available about its safety in routine clinical use.
METHODS: Data on mifepristone abortion use from the Planned Parenthood Federation of America, the largest provider of mifepristone abortion in the United States, from 2001 through the first quarter of 2004 were collected using a centralized reporting system. Over the study period, 95,163 mifepristone abortions were provided. Reportable events are complications requiring inpatient or outpatient hospital treatment.
RESULTS: Overall, 2.2 per 1000 women (95% CI 1.9-2.5) experienced a complication, most commonly, heavy bleeding. Mifepristone abortion mortality is estimated to be 1.1 per 100,000 based on one death (95% CI 0.3-5.9).
CONCLUSIONS: The safety of mifepristone is high; few serious medical complications occur in routine clinical use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16102550     DOI: 10.1016/j.contraception.2005.03.011

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

Review 1.  Medical liability insurance as a barrier to the provision of abortion services in family medicine.

Authors:  Christine E Dehlendorf; Kevin Grumbach
Journal:  Am J Public Health       Date:  2008-08-13       Impact factor: 9.308

2.  Reduction in infection-related mortality since modifications in the regimen of medical abortion.

Authors:  James Trussell; Deborah Nucatola; Mary Fjerstad; E Steve Lichtenberg
Journal:  Contraception       Date:  2013-12-11       Impact factor: 3.375

3.  Knowledge of medication abortion among adolescent medicine providers.

Authors:  Mandy S Coles; Kevin K Makino; Rachael Phelps
Journal:  J Adolesc Health       Date:  2011-10-14       Impact factor: 5.012

4.  Uses of misoprostol in obstetrics and gynecology.

Authors:  Rebecca Allen; Barbara M O'Brien
Journal:  Rev Obstet Gynecol       Date:  2009

5.  Insights in Public Health: Equitable Access to Abortion Care in Hawai'i: Identifying Gaps and Solutions.

Authors:  Ghazaleh Moayedi; Chevelle Davis
Journal:  Hawaii J Med Public Health       Date:  2018-07

6.  Rates of serious infection after changes in regimens for medical abortion.

Authors:  Mary Fjerstad; James Trussell; Irving Sivin; E Steve Lichtenberg; Vanessa Cullins
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

7.  Significant adverse events and outcomes after medical abortion.

Authors:  Kelly Cleland; Mitchell D Creinin; Deborah Nucatola; Montsine Nshom; James Trussell
Journal:  Obstet Gynecol       Date:  2013-01       Impact factor: 7.661

8.  A Study of Incomplete Abortion Following Medical Method of Abortion (MMA).

Authors:  Anuya A Pawde; Arun Ambadkar; Anahita R Chauhan
Journal:  J Obstet Gynaecol India       Date:  2015-02-05

9.  Implications of Zika virus and congenital Zika syndrome for the number of live births in Brazil.

Authors:  Marcia C Castro; Qiuyi C Han; Lucas R Carvalho; Cesar G Victora; Giovanny V A França
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

10.  Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity.

Authors:  Aaron DeBono; David R Thomas; Lindsay Lundberg; Chelsea Pinkham; Ying Cao; J Dinny Graham; Christine L Clarke; Kylie M Wagstaff; Sharon Shechter; Kylene Kehn-Hall; David A Jans
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.